{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:23:56Z","timestamp":1793741036963,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J0676"],"award-info":[{"award-number":["2024A03J0676"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ultrasonics Sonochemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ultsonch.2025.107352","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T18:32:06Z","timestamp":1745692326000},"page":"107352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Ultrasound-driven ROS-scavenging nanobubbles for synergistic NASH treatment via FXR activation"],"prefix":"10.1016","volume":"118","author":[{"given":"Jianru","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CuiYan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichuang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ultsonch.2025.107352_b0005","first-page":"159","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101238","article-title":"Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): recent advances","volume":"91","author":"Musso","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ultsonch.2025.107352_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ultsonch.2025.107352_b0020","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.3390\/ijms25074010","article-title":"Innovative molecular targets and therapeutic approaches in nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis (NAFLD\/NASH) 3.0","volume":"25","author":"Vairetti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ultsonch.2025.107352_b0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.actbio.2023.04.002","article-title":"Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR\/miR-34a\/SIRT1 regulatory loop","volume":"164","author":"Kong","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ultsonch.2025.107352_b0030","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41467-023-38259-1","article-title":"Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1","volume":"14","author":"Pang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ultsonch.2025.107352_b0035","doi-asserted-by":"crossref","unstructured":"M. Karimi, B. Abiri, P.C. Guest, M. Vafa, Therapeutic effects of resveratrol resveratrol on nonalcoholic fatty liver disease through inflammatory, oxidative stress oxidative stress, metabolic, and epigenetic modifications, in: P.C. Guest (Ed.) Physical Exercise and Natural and Synthetic Products in Health and Disease, Springer US, New York, NY, 2022, pp. 19\u201335, doi: 10.1007\/978-1-0716-1558-4_2.","DOI":"10.1007\/978-1-0716-1558-4_2"},{"key":"10.1016\/j.ultsonch.2025.107352_b0040","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0045","first-page":"312","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (vol 394, pg 2184, 2019)","volume":"396","author":"Younossi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ultsonch.2025.107352_b0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1142\/S0192415X24500137","article-title":"Natural products in the modulation of farnesoid X receptor against nonalcoholic fatty liver disease","volume":"52","author":"Wang","year":"2024","journal-title":"Am J Chinese Med"},{"key":"10.1016\/j.ultsonch.2025.107352_b0055","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.ultsonch.2025.107352_b0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/nu15051255","article-title":"Gamma-muricholic acid inhibits nonalcoholic steatohepatitis: abolishment of steatosis-dependent peroxidative impairment by FXR\/SHP\/LXR\u03b1\/FASN signaling","volume":"15","author":"Xie","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.ultsonch.2025.107352_b0065","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1002\/hep4.2066","article-title":"Population-based meta-analysis and gene-set enrichment identifies FXR\/RXR pathway as common to fatty liver disease and serum lipids","volume":"6","author":"Handelman","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ultsonch.2025.107352_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110389","article-title":"IL-6-induced FOXO1 activity determines the dynamics of metabolism in CD8 T cells cross-primed by liver sinusoidal endothelial cells","volume":"38","author":"Dudek","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ultsonch.2025.107352_b0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.apsb.2022.08.019","article-title":"SIRT1 activation synergizes with FXR agonism in hepatoprotection governing nucleocytoplasmic shuttling and degradation of FXR","volume":"13","author":"Cui","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ultsonch.2025.107352_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000002471","article-title":"Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"35","author":"Li","year":"2023","journal-title":"Eur. J. Gastroen. Hepat."},{"key":"10.1016\/j.ultsonch.2025.107352_b0085","article-title":"Strategies to improve resveratrol systemic and topical bioavailability: an update","volume":"8","author":"Intagliata","year":"2019","journal-title":"Antioxidants-Basel"},{"key":"10.1016\/j.ultsonch.2025.107352_b0090","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1021\/acs.analchem.3c02948","article-title":"Employing the anchor DSPE-PEG as a redox probe for ratiometric electrochemical detection of surface proteins on extracellular vesicles with aptamers","volume":"95","author":"Chang","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ultsonch.2025.107352_b0095","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ultsonch.2025.107352_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev-pharmtox-010617-052545","article-title":"Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: emerging therapies","volume":"58","author":"Wattacheril","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.950141","article-title":"Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.3029864","article-title":"Bilirubin is an antioxidant of possible physiological importance","volume":"235","author":"Stocker","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ultsonch.2025.107352_b0115","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1093\/eurheartj\/ehac431","article-title":"Exerkine fibronectin type-III domain-containing protein 5\/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability","volume":"43","author":"Chi","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ultsonch.2025.107352_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ultsonch.2025.107352_b0135","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0140","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ultsonch.2025.107352_b0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ultsonch.2025.107352_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111650","article-title":"Immunomodulatory functions of FXR","volume":"551","author":"Fiorucci","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0160","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1074\/jbc.RA118.005309","article-title":"Hepatocyte-specific Sirt6 deficiency impairs ketogenesis","volume":"294","author":"Chen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ultsonch.2025.107352_b0165","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ultsonch.2025.107352_b0170","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.3259","article-title":"Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability","volume":"19","author":"Pajvani","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ultsonch.2025.107352_b0175","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.2337\/db13-0769","article-title":"Hepatic Notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease","volume":"62","author":"Valenti","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ultsonch.2025.107352_b0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial dysfunction and signaling in chronic liver diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ultsonch.2025.107352_b0185","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ultsonch.2025.107352_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.134496","article-title":"Cost-effective and natural-inspired lotus root\/GelMA scaffolds enhanced wound healing via ROS scavenging, angiogenesis and reepithelialization","volume":"278","author":"Huang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ultsonch.2025.107352_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213779","article-title":"Hybrid gelatin-ascorbyl phosphate scaffolds accelerate diabetic wound healing ROS scavenging, angiogenesis and collagen remodeling","volume":"158","author":"Zhang","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ultsonch.2025.107352_b0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radical. Bio Med."},{"key":"10.1016\/j.ultsonch.2025.107352_b0205","first-page":"841","article-title":"Antioxidant activities of bile pigments","volume":"6","author":"Stocker","year":"2004","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ultsonch.2025.107352_b0210","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1073\/pnas.0813132106","article-title":"Bilirubin and glutathione have complementary antioxidant and cytoprotective roles","volume":"106","author":"Sedlak","year":"2009","journal-title":"PNAS"}],"container-title":["Ultrasonics Sonochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350417725001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350417725001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:52:13Z","timestamp":1762368733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350417725001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"alternative-id":["S1350417725001312"],"URL":"https:\/\/doi.org\/10.1016\/j.ultsonch.2025.107352","relation":{},"ISSN":["1350-4177"],"issn-type":[{"value":"1350-4177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasound-driven ROS-scavenging nanobubbles for synergistic NASH treatment via FXR activation","name":"articletitle","label":"Article Title"},{"value":"Ultrasonics Sonochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ultsonch.2025.107352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107352"}}